Novartis gets grant to develop multiple sclerosis drug from Peptimmune
In a separate but related agreement, the MPM Bio IV NVS Strategic Fund made an equity investment in Peptimmune. In the event that Novartis exercises the option to
Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics.